<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: ZymoGenetics Plays Hardball, Asks FDA to Pull Competing Drug Off Market Because of Safety</title>
	<atom:link href="http://www.xconomy.com/seattle/2009/08/20/zymogenetics-plays-hardball-asks-fda-to-pull-competing-drug-off-market-because-of-safety/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/seattle/2009/08/20/zymogenetics-plays-hardball-asks-fda-to-pull-competing-drug-off-market-because-of-safety/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 12:29:49 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: Oliver Ochs</title>
		<link>http://www.xconomy.com/seattle/2009/08/20/zymogenetics-plays-hardball-asks-fda-to-pull-competing-drug-off-market-because-of-safety/comment-page-1/#comment-76286</link>
		<dc:creator>Oliver Ochs</dc:creator>
		<pubDate>Thu, 20 Aug 2009 18:59:29 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=38324#comment-76286</guid>
		<description>Interesting in that it&#039;s a superior product and not much more expensive ($90 for recothromb versus $70 for the bovine product at my institution).  We&#039;ve switched for all perivascular needle procedures in our department but the hospital still uses the bovine product in open surgery.  I don&#039;t see how the admittedly small risk of limb loss and death don&#039;t warrent the small extra cost. I think the biggest factor is physician ignorance that bovine thrombin may have systemic or regional effect when administered locally.</description>
		<content:encoded><![CDATA[<p>Interesting in that it’s a superior product and not much more expensive ($90 for recothromb versus $70 for the bovine product at my institution).  We’ve switched for all perivascular needle procedures in our department but the hospital still uses the bovine product in open surgery.  I don’t see how the admittedly small risk of limb loss and death don’t warrent the small extra cost. I think the biggest factor is physician ignorance that bovine thrombin may have systemic or regional effect when administered locally.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: ZymoGenetics Plays Hardball, Asks FDA to Pull Competing Drug Off &#8230; &#124; blooddonors</title>
		<link>http://www.xconomy.com/seattle/2009/08/20/zymogenetics-plays-hardball-asks-fda-to-pull-competing-drug-off-market-because-of-safety/comment-page-1/#comment-76274</link>
		<dc:creator>ZymoGenetics Plays Hardball, Asks FDA to Pull Competing Drug Off &#8230; &#124; blooddonors</dc:creator>
		<pubDate>Thu, 20 Aug 2009 17:45:07 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=38324#comment-76274</guid>
		<description>[...] Continue reading here: ZymoGenetics Plays Hardball, Asks FDA to Pull Competing Drug Off ... [...]</description>
		<content:encoded><![CDATA[<p>[...] Continue reading here: ZymoGenetics Plays Hardball, Asks FDA to Pull Competing Drug Off … [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

